Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 ...

The 2022 Option Agreement between Astellas and Taysha has expiredRegaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus ...

The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic fle ...

How new front-of-pack labels aim to highlight ultra-processed foods (UPFs). Explore three emerging labelling schemes designed ...

Regeneron Pharmaceuticals, Inc. REGN announced updated data on its investigational gene therapy DB-OTO from the CHORD study.

Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene ...

FDA fast track designation for NG-350A aims to expedite its development for mismatch repair-proficient locally advanced ...

Oxipital AI's approach combines 3D scanning with AI-generated training data to inspect products without manual image ...

From the 2010s to the present, the existing technologies in the clinic and operating room have been improved with the goals ...

Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.

Every time Sorin publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...